You Won't Regret Reading the Facts on Teleflex.

Large-cap Health Care company Teleflex has logged a -7.3% change today on a trading volume of 334,501. The average volume for the stock is 319,686.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. Based in Wayne, United States the company has 15,500 full time employees and a market cap of $11,837,683,712. Teleflex currently offers its equity investors a dividend that yields 0.5% per year.

The company is now trading -7.03% away from its average analyst target price of $271.23 per share. The 13 analysts following the stock have set target prices ranging from $241.0 to $330.0, and on average give Teleflex a rating of hold.

Over the last year, TFX shares have gone down by -2.0%, which represents a difference of -1.0% when compared to the S&P 500. The stock's 52 week high is $293.81 per share and its 52 week low is $182.65. Based on Teleflex's compound average operating margin growth of 1.9% over the last 4 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2022-12-31 2,791,041 1,259,954 54.86 -0.53
2021-12-31 2,809,563 1,259,961 55.15 5.61
2020-12-31 2,537,156 1,212,282 52.22 -9.14
2019-12-31 2,595,362 1,103,750 57.47 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.